Strategy
Build-vs-partner, three-phase go-to-market, North Star metric, and the risk plan including the agentic-lab interface controls.
18-month priorities
Close Apollo partnership
Joint biobank MoU, federated learning architecture, revenue-share terms. Without this, no moat.
Land 3 anchor customers
1 generic pharma, 1 hospital research arm, 1 biotech startup. Co-develop OmicsCloud + first Discovery Sprint.
Ship LabOS sidecar
STARLIMS / Benchling Tier-1 integration live. First closed-loop discovery cycles on the North Star metric.
Do not build FAL in Phase 1. Partner CROs for execution; own the agent mesh, experimental graph, and Apollo data layer. Revisit FAL Pods at $3M+ ARR. See Build vs Partner.
Build vs Partner →
The FAL decision — why we do not own robots in Phase 1.
Go-to-Market →
Three-phase sequence: Apollo anchor → APAC bridge → global expansion.
North Star & KPIs →
Closed-loop discovery cycles per quarter and full KPI grid.
Risks & Mitigation →
Enterprise risks plus the dedicated agentic-lab interface risk plan.